Clinical Research Directory
Browse clinical research sites, groups, and studies.
Preoperative ROS1-TKI Therapy for ROS1 Fusion-Positive Locally Advanced Lung Adenocarcinoma
Sponsor: Peking University Cancer Hospital & Institute
Summary
This multicenter retrospective study evaluates preoperative ROS1-TKI therapy in patients with ROS1 fusion-positive locally advanced lung adenocarcinoma. Patients who received ROS1-TKI therapy before surgical resection were retrospectively identified from four tertiary hospitals in China. The study describes clinicopathological characteristics, radiographic response, treatment-related adverse events, surgical outcomes, pathological response, and follow-up outcomes.
Official title: Preoperative ROS1-TKI Therapy for ROS1 Fusion-Positive Locally Advanced Lung Adenocarcinoma: A Multicenter Retrospective Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
12
Start Date
2021-07-01
Completion Date
2025-11-17
Last Updated
2026-07-15
Healthy Volunteers
No
Conditions
Interventions
ROS1-TKI Therapy
Preoperative ROS1 tyrosine kinase inhibitor therapy, including entrectinib or crizotinib, administered according to routine clinical practice before surgical resection.
Locations (1)
Peking University Cancer Hospital & Institute, Beijing, Beijing 100142
Beijing, Beijing Municipality, China